ElevateBio is seeking out partnerships for its lead gene therapy after the construct reduced the levels of a toxic protein in ...

The molecular glue wave that first began years ago is still swelling, with Eli Lilly earmarking approximately $1.25 billion ...

Adagio will now put its resources toward completing the pivotal U.S. trial of its vCLAS catheter, and its subsequent ...

Praxis Precision Medicines has been blindsided by a recommendation to stop a phase 3 essential tremor trial. Two months after ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

Gene therapy maker bluebird bio’s 15-year flight has landed in the nest of private equity firms Carlyle and SK Capital in a ...

Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis D, but it's pausing further development in ...

Kallyope has slipped out results from a phase 2 trial of its obesity candidates, linking the combination of the two oral ...

The Department of Health and Human Services is re-evaluating a $590 million contract for avian influenza mRNA vaccines that ...

AbbVie-partnered Mission Therapeutics is tweaking its trajectory, closing a preclinical laboratory in the U.K. to focus on ...

When Silence Therapeutics unveiled its latest zerlasiran phase 2 data at the American Heart Association (AHA) conference in ...

Nxera Pharma has sold the Asia-Pacific rights to Idorsia's phase 3-stage autoimmune drug to Viatris for $10 million upfront.